To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2012

Primary Completion Date

May 27, 2014

Study Completion Date

May 27, 2014

Conditions

Alcoholism

Interventions

DRUG

GSK1521498

White HPMC capsule containing 10 mg of GSK1521498

DRUG

Naltrexone (NTX)

Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX

DRUG

Placebo

Matching placebo capsules to GSK1521498 or NTX

Trial Locations (1)

GSK Investigational Site, Cambridge